Chief Scientific Officer
Wendy has over 30 years of experience in drug discovery with more than 15 years as a member of the P2Y12 antagonist project team in Astra/AstraZeneca. She designed, developed and implemented innovative test systems that were pivotal to the discovery and profiling of the anti-platelet agents Brilinta (ticagrelor) and Kengreal (cangrelor). Wendy joined Platelet Services in 2021, from the successful CRO, XenoGesis, where she was Director of Cell-Based Assay Development and managed a team of 13. Wendy brings to Platelet Services a deep knowledge of the drug discovery process and of tailoring test systems to the requirements of projects at various stages of the pipeline.